Literature DB >> 28736315

The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions.

Felipe C Geyer1, Fresia Pareja1, Britta Weigelt1, Emad Rakha2, Ian O Ellis2, Stuart J Schnitt3, Jorge S Reis-Filho4.   

Abstract

Triple-negative breast cancer is viewed clinically as an aggressive subgroup of breast cancer. In fact, most triple-negative breast cancers are poor-prognosis tumors with a complex genomic landscape. However, triple-negative disease is vastly heterogeneous, encompassing multiple entities with marked genetic, transcriptional, histologic, and clinical differences, with neoplasms in this group ranging from low to high grade. Among the less common low-grade triple-negative lesions, two large subgroups, both with a rather indolent behavior, can be distinguished: a low-grade triple-negative breast neoplasia family, which includes nonobligate precursors of triple-negative breast cancer, and, despite being low-grade, harbors the complex genomic landscape of usual triple-negative breast cancer, and the salivary gland-like tumors of the breast, lacking all the cardinal molecular features of conventional triple-negative breast cancer and underpinned by specific fusion genes or hotspot mutations, which may be of diagnostic and possibly therapeutic utility. Progression to high-grade triple-negative breast cancer likely occurs in both subgroups but at different rates. In this review, we describe the heterogeneity of triple-negative disease, focusing on the histologic and molecular features of the low-grade lesions. Recognition that triple-negative breast cancer is an operational term and that triple-negative disease is heterogeneous and includes low-grade forms driven by distinct sets of genetic alterations is germane to the successful implementation of precision medicine.
Copyright © 2017 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28736315      PMCID: PMC5809519          DOI: 10.1016/j.ajpath.2017.03.016

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  96 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

Review 2.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

3.  Secretory Carcinoma of the Skin Harboring ETV6 Gene Fusions: A Cutaneous Analogue to Secretory Carcinomas of the Breast and Salivary Glands.

Authors:  Justin A Bishop; Janis M Taube; Albert Su; Scott W Binder; Dmitry V Kazakov; Michal Michal; William H Westra
Journal:  Am J Surg Pathol       Date:  2017-01       Impact factor: 6.394

4.  Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer.

Authors:  So-Youn Jung; Hyun Yul Kim; Byung-Ho Nam; Sun Young Min; Seung Ju Lee; Chansung Park; Youngmee Kwon; Eun-A Kim; Kyoung Lan Ko; Kyung Hwan Shin; Keun Seok Lee; In Hae Park; Seeyoun Lee; Seok Won Kim; Han-Sung Kang; Jungsil Ro
Journal:  Breast Cancer Res Treat       Date:  2010-02-09       Impact factor: 4.872

Review 5.  Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways.

Authors:  Lionel Larue; Alfonso Bellacosa
Journal:  Oncogene       Date:  2005-11-14       Impact factor: 9.867

6.  Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

Authors:  Gunter von Minckwitz; Andreas Schneeweiss; Sibylle Loibl; Christoph Salat; Carsten Denkert; Mahdi Rezai; Jens U Blohmer; Christian Jackisch; Stefan Paepke; Bernd Gerber; Dirk M Zahm; Sherko Kümmel; Holger Eidtmann; Peter Klare; Jens Huober; Serban Costa; Hans Tesch; Claus Hanusch; Jörn Hilfrich; Fariba Khandan; Peter A Fasching; Bruno V Sinn; Knut Engels; Keyur Mehta; Valentina Nekljudova; Michael Untch
Journal:  Lancet Oncol       Date:  2014-04-30       Impact factor: 41.316

7.  Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma.

Authors:  Hyunseok Kang; Marietta Tan; Justin A Bishop; Siân Jones; Mark Sausen; Patrick K Ha; Nishant Agrawal
Journal:  Clin Cancer Res       Date:  2016-06-23       Impact factor: 12.531

8.  Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations.

Authors:  Elena Guerini-Rocco; Salvatore Piscuoglio; Charlotte K Y Ng; Felipe C Geyer; Maria R De Filippo; Carey A Eberle; Muzaffar Akram; Nicola Fusco; Shu Ichihara; Rita A Sakr; Yasushi Yatabe; Anne Vincent-Salomon; Emad A Rakha; Ian O Ellis; Y Hannah Wen; Britta Weigelt; Stuart J Schnitt; Jorge S Reis-Filho
Journal:  J Pathol       Date:  2016-04       Impact factor: 7.996

9.  Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype?

Authors:  Rachael Natrajan; Maryou B K Lambros; Felipe C Geyer; Caterina Marchio; David S P Tan; Radost Vatcheva; Kai-Keen Shiu; Daniela Hungermann; Socorro Maria Rodriguez-Pinilla; Jose Palacios; Alan Ashworth; Horst Buerger; Jorge S Reis-Filho
Journal:  Genes Chromosomes Cancer       Date:  2009-04       Impact factor: 5.006

10.  What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).

Authors:  A Drilon; G Li; S Dogan; M Gounder; R Shen; M Arcila; L Wang; D M Hyman; J Hechtman; G Wei; N R Cam; J Christiansen; D Luo; E C Maneval; T Bauer; M Patel; S V Liu; S H I Ou; A Farago; A Shaw; R F Shoemaker; J Lim; Z Hornby; P Multani; M Ladanyi; M Berger; N Katabi; R Ghossein; A L Ho
Journal:  Ann Oncol       Date:  2016-02-15       Impact factor: 32.976

View more
  30 in total

Review 1.  Molecular Classification and Future Therapeutic Challenges of Triple-negative Breast Cancer.

Authors:  Nikolaos Garmpis; Christos Damaskos; Anna Garmpi; Konstantinos Nikolettos; Dimitrios Dimitroulis; Evangelos Diamantis; Paraskevi Farmaki; Alexandros Patsouras; Errika Voutyritsa; Athanasios Syllaios; Constantinos G Zografos; Efstathios A Antoniou; Nikos Nikolettos; Alkiviadis Kostakis; Konstantinos Kontzoglou; Dimitrios Schizas; Afroditi Nonni
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  Whole-exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast.

Authors:  Francisco Beca; Simon S K Lee; Fresia Pareja; Arnaud Da Cruz Paula; Pier Selenica; Lorenzo Ferrando; Rodrigo Gularte-Mérida; Hannah Y Wen; Hong Zhang; Elena Guerini-Rocco; Emad A Rakha; Britta Weigelt; Jorge S Reis-Filho
Journal:  Histopathology       Date:  2019-10-13       Impact factor: 5.087

3.  MiR-214-3p regulates the viability, invasion, migration and EMT of TNBC cells by targeting ST6GAL1.

Authors:  Yun Tao; Zhijing Zhao; Junfeng Ma; Liying Dong; Ying Liang; Siqi Li; Ying Mao; Yan Li; Yi Zhang
Journal:  Cytotechnology       Date:  2019-11-08       Impact factor: 2.058

Review 4.  Protein biomarkers for subtyping breast cancer and implications for future research.

Authors:  Claudius Mueller; Amanda Haymond; Justin B Davis; Alexa Williams; Virginia Espina
Journal:  Expert Rev Proteomics       Date:  2018-01-03       Impact factor: 3.940

5.  Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma.

Authors:  Fresia Pareja; Pier Selenica; David N Brown; Ana P M Sebastiao; Edaise M da Silva; Arnaud Da Cruz Paula; Angela Del; Li Fu; Britta Weigelt; Edi Brogi; Jorge S Reis-Filho; Hannah Y Wen
Journal:  Histopathology       Date:  2019-06-13       Impact factor: 5.087

6.  Impact of biomarkers and genetic profiling on breast cancer prognostication: A comparative analysis of the 8th edition of breast cancer staging system.

Authors:  Esther C Yoon; Christopher Schwartz; Edi Brogi; Katia Ventura; Hannah Wen; Farbod Darvishian
Journal:  Breast J       Date:  2019-06-13       Impact factor: 2.431

7.  The HTN3-MSANTD3 Fusion Gene Defines a Subset of Acinic Cell Carcinoma of the Salivary Gland.

Authors:  Simon Andreasen; Sushama Varma; Nicholas Barasch; Lester D R Thompson; Markku Miettinen; Lisa Rooper; Edward B Stelow; Tina K Agander; Raja R Seethala; Simion I Chiosea; Preben Homøe; Irene Wessel; Stine R Larsen; Daiva Erentaite; Justin A Bishop; Benedicte P Ulhøi; Katalin Kiss; Linea C Melchior; Jonathan R Pollack; Robert B West
Journal:  Am J Surg Pathol       Date:  2019-04       Impact factor: 6.394

Review 8.  Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review.

Authors:  F Giugliano; J Uliano; V A A Zia; D Trapani; A Marra; G Viale; E Ferraro; A Esposito; C Criscitiello; P D'amico; G Curigliano
Journal:  Breast Cancer Res Treat       Date:  2021-05-27       Impact factor: 4.872

Review 9.  Triple-negative breast cancer: A run-through of features, classification and current therapies.

Authors:  Meghana Manjunath; Bibha Choudhary
Journal:  Oncol Lett       Date:  2021-05-05       Impact factor: 2.967

10.  Increases in Tumor N-Glycan Polylactosamines Associated with Advanced HER2-Positive and Triple-Negative Breast Cancer Tissues.

Authors:  Danielle A Scott; Rita Casadonte; Barbara Cardinali; Laura Spruill; Anand S Mehta; Franca Carli; Nicole Simone; Mark Kriegsmann; Lucia Del Mastro; Joerg Kriegsmann; Richard R Drake
Journal:  Proteomics Clin Appl       Date:  2019-01       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.